XML 36 R23.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail) (USD $) | 9 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2013 | Dec. 31, 2012 | Oct. 31, 2009 California Institute for Regenerative Medicine [Member] | Sep. 30, 2013 California Institute for Regenerative Medicine [Member] | Sep. 30, 2012 California Institute for Regenerative Medicine [Member] | Sep. 30, 2013 California Institute for Regenerative Medicine [Member] | Sep. 30, 2012 California Institute for Regenerative Medicine [Member] | Apr. 30, 2011 CHDI Foundation, Inc. [Member] | Sep. 30, 2013 CHDI Foundation, Inc. [Member] | Sep. 30, 2012 CHDI Foundation, Inc. [Member] | Sep. 30, 2013 CHDI Foundation, Inc. [Member] | Sep. 30, 2012 CHDI Foundation, Inc. [Member] | Dec. 31, 2012 CHDI Foundation, Inc. [Member] | Mar. 31, 2012 Juvenile Diabetes Research Foundation International [Member] | Jan. 31, 2010 Juvenile Diabetes Research Foundation International [Member] | Sep. 30, 2013 Juvenile Diabetes Research Foundation International [Member] | Sep. 30, 2012 Juvenile Diabetes Research Foundation International [Member] | Sep. 30, 2013 Juvenile Diabetes Research Foundation International [Member] | Sep. 30, 2012 Juvenile Diabetes Research Foundation International [Member] | Oct. 31, 2006 Juvenile Diabetes Research Foundation International [Member] | Sep. 30, 2013 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Sep. 30, 2012 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Sep. 30, 2013 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Sep. 30, 2012 License agreement terms [Member] California Institute for Regenerative Medicine [Member] | Jun. 30, 2012 Shire AG [Member] Targets | Jan. 31, 2012 Shire AG [Member] Targets | Sep. 30, 2013 Shire AG [Member] | Sep. 30, 2012 Shire AG [Member] | Sep. 30, 2013 Shire AG [Member] Product | Sep. 30, 2012 Shire AG [Member] | Apr. 30, 2013 Sigma-Aldrich Corporation [Member] | Oct. 31, 2009 Sigma-Aldrich Corporation [Member] | Jul. 31, 2007 Sigma-Aldrich Corporation [Member] | Sep. 30, 2013 Sigma-Aldrich Corporation [Member] | Sep. 30, 2012 Sigma-Aldrich Corporation [Member] | Sep. 30, 2013 Sigma-Aldrich Corporation [Member] | Sep. 30, 2012 Sigma-Aldrich Corporation [Member] | Oct. 31, 2009 Sigma-Aldrich Corporation [Member] Upfront license fee [Member] | Sep. 30, 2013 Sigma-Aldrich Corporation [Member] License agreement terms [Member] | Sep. 30, 2012 Sigma-Aldrich Corporation [Member] License agreement terms [Member] | Sep. 30, 2013 Sigma-Aldrich Corporation [Member] License agreement terms [Member] | Sep. 30, 2012 Sigma-Aldrich Corporation [Member] License agreement terms [Member] | Oct. 31, 2009 Sigma-Aldrich Corporation [Member] License agreement terms [Member] | Oct. 31, 2005 Dow AgroSciences [Member] | Sep. 30, 2013 Dow AgroSciences [Member] | Sep. 30, 2012 Dow AgroSciences [Member] | Sep. 30, 2013 Dow AgroSciences [Member] | Sep. 30, 2012 Dow AgroSciences [Member] | Oct. 31, 2005 Dow AgroSciences [Member] Minimum [Member] | Oct. 31, 2005 Dow AgroSciences [Member] Maximum [Member] | Oct. 31, 2005 Dow AgroSciences [Member] License agreement terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate number of gene targets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of initial gene targets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of gene targets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional gene targets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research program to develop laboratory research reagents |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 13,000,000 |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  | $ 15,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Potential amount to be funded for certain Shire milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 213,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IND or CTA submission amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of products approved |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  | 201,000 | 428,000 | 711,000 | 1,035,000 |  |  |  |  |  |  | 2,300,000 |  |  |  |  |  |  | 4,000,000
Deferred revenue | 2,300,000 | 2,304,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,500,000 |  | 9,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreement Related Costs and Expenses |  |  |  | 500,000 | 300,000 | 1,400,000 | 900,000 |  | 0 | 300,000 | 0 | 1,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 | 2,200,000 | 10,300,000 | 3,800,000 |  |  |  |  |  |  |  |  | 100,000 | 100,000 | 100,000 | 300,000 |  |  | 0 | 100,000 | 0 | 400,000 |  |  |
Common stock, valued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Public offering, common stock shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 636,133 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenues expected to be received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |
Reduced royalty rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding available under the amended agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue attributable to research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,300,000 |  |  | 101,000 |  | 1,351,000 | 1,000,000 |  |  |  |  |  |  |  | 0 | 400,000 | 0 | 1,300,000 |  |  |
One-time license fee earned on exercise of option |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,000,000 |  |  |  |  |  |  |
Percentage of royalties to be received from sublicensing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |
Annual fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000.0 | 3,000,000 |
Minimum sublicense annual fees specific reckoning period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 years |  |  |  |  |  |  |
Fee due |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,300,000 |  |  |  |  |  |  |
Funds due under the agreement |  |  | 14,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement to receive |  |  | 4 years |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected amount to be received for research and development |  |  | 5,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement date |  |  | Oct. 31, 2009 |  |  |  |  | Apr. 30, 2011 |  |  |  |  |  |  |  |  |  |  |  | Oct. 31, 2006 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables from sale against the grant funded to entity from sale of product | Two times the amount Sangamo receives in funding under the agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  |  |  | 0 | 300,000 | 0 | 1,100,000 |  |  |  | 0 | 0 | 0 | 800,000 |  | 500,000 | 300,000 | 1,200,000 | 900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funds due under agreement |  |  |  |  |  |  |  | 1,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual agreement termination date |  |  |  |  |  |  |  |  |  |  | Aug. 30, 2012 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funds due under agreement as per amendment |  |  |  |  |  |  |  |  |  |  |  |  | 2,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grant funding amount maximum under amended agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Received for work performed under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payment under agreement. + References No definition available. + Details
Name: | sgmo_AdditionalMilestonePaymentUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognized
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate additional revenue recognition milestone method revenue to be recognized on acceptance of application. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueToBeRecognizedOnAcceptanceOfApplication
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate number of gene targets. + References No definition available. + Details
Name: | sgmo_AggregateNumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement date. + References No definition available. + Details
Name: | sgmo_AgreementDate
Namespace Prefix: | sgmo_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Definition Agreement to receive. + References No definition available. + Details
Name: | sgmo_AgreementToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual fees related to agreement. + References No definition available. + Details
Name: | sgmo_AnnualFeesRelatedToAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement related costs and expenses. + References No definition available. + Details
Name: | sgmo_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual agreement termination date. + References No definition available. + Details
Name: | sgmo_ContractualAgreementTerminationDate
Namespace Prefix: | sgmo_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected amount to be received for research and development. + References No definition available. + Details
Name: | sgmo_ExpectedAmountToBeReceivedForResearchAndDevelopment
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fee due. + References No definition available. + Details
Name: | sgmo_FeeDue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funds due under agreement. + References No definition available. + Details
Name: | sgmo_FundsDueUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Grant funding amount. + References No definition available. + Details
Name: | sgmo_GrantFundingAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Grant funding amount maximum under amended agreement. + References No definition available. + Details
Name: | sgmo_GrantFundingAmountMaximumUnderAmendedAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum sublicense annual fees specific reckoning period. + References No definition available. + Details
Name: | sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfAdditionalGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of initial gene targets. + References No definition available. + Details
Name: | sgmo_NumberOfInitialGeneTargets
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition One time license fee earned. + References No definition available. + Details
Name: | sgmo_OneTimeLicenseFeeEarned
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of royalties to be received from sublicensing. + References No definition available. + Details
Name: | sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Post amendment funds due under agreement. + References No definition available. + Details
Name: | sgmo_PostAmendmentFundsDueUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential Royalty Payments To Entity + References No definition available. + Details
Name: | sgmo_PotentialRoyaltyPaymentsToEntity
Namespace Prefix: | sgmo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds received for work performed under agreement. + References No definition available. + Details
Name: | sgmo_ProceedsReceivedForWorkPerformedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reduced royalty rate. + References No definition available. + Details
Name: | sgmo_ReducedRoyaltyRate
Namespace Prefix: | sgmo_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research grant revenue. + References No definition available. + Details
Name: | sgmo_ResearchGrantRevenue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty revenues expected to be received. + References No definition available. + Details
Name: | sgmo_RoyaltyRevenuesExpectedToBeReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | sgmo_UpfrontLicenseFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration